Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cirtuvivint in advanced solid tumors
NCT03355066Phase 1Terminated
- Sponsor
- Biosplice Therapeutics
- Start
- Nov 2017
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cirtuvivint in solid tumor, prostate cancer (PCa), non-small cell lung cancer (NSCLC) and 4 more, sponsored by Biosplice Therapeutics. Primary endpoints: Maximum Tolerated Dose at 28 days, Treatment-Emergent Adverse Events at 5 years and 5 more. Started Nov 2017; status: terminated.
02
Drugs
cirtuvivint
03
Conditions
solid tumorprostate cancer (PCa)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03355066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03355066.